



Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the 39th Annual J.P. Morgan Healthcare Conference. The conference, which will take place January 11-14, 2021, is being conducted with a virtual format.

As a centerpiece of the update, Dr. Goldsmith will announce the entry of two first-in-class RAS(ON) Inhibitor programs into IND-enabling development and will discuss the profiles of these development candidates and next steps for advancing them. Dr. Goldsmith will also provide an update on the company's three RAS Companion Inhibitors, including RMC-4630 (SHP2 inhibitor), RMC-5552 (mTORC1-selective inhibitor), and a new member, RMC-5845 (SOS1-selective inhibitor).

Details of Revolution Medicines' presentation are as follows:

- **39th Annual J.P. Morgan Healthcare Conference**
Conference Date: January 11-14, 2021
Presentation Time/Date: 5:20 p.m. Eastern on Tuesday, January 12, 2021
Format: Virtual conference; webcast available

To access the live webcast of the presentation, please visit the "Events & Presentations" page within the Investors section of Revolution Medicines' website at <https://ir.revmed.com/events-and-presentations>. Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines' website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors include RMC-6291, RMC-6236 and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors include RMC-4630, RMC-5552, and RMC-5845.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Revolution Medicines' development plans and timelines and the company's ability to advance its portfolio and R&D pipeline, including its RAS(ON) Inhibitor programs that are in IND-enabling development. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 sdiaz@vidasp.com For Media: Vida Strategic Partners Tim Brons 415-675-7402 tbrons@vidasp.com